Ioflupan (123i) Rotop

Ioflupane, the active ingredient in Ioflupan (123i) Rotop, is a radiopharmaceutical presented as a sterile injectable solution for intravenous use. It enables visualization of dopamine transporter density to assist in the assessment of Parkinsonian syndromes in adult patients.

GNH USA supplies Ioflupan (123i) Rotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and clinical use. Our distribution network ensures timely delivery to imaging centers across Europe, Asia, Africa and the Americas.

Ioflupan (Ioflupane) is employed in nuclear medicine to evaluate dopaminergic pathways in movement‑disorder diagnostics. - Parkinsonian syndrome: assists in detecting presynaptic dopaminergic deficits to support diagnosis. - Parkinson's disease: helps differentiate Parkinson's disease from other parkinsonian disorders. - Dementia with Lewy bodies: provides imaging evidence of reduced dopamine transporter availability.

Ioflupan may be associated with adverse reactions related to the radiopharmaceutical itself or the injection procedure.

Common Side Effects: - Nausea: mild, transient feeling of queasiness. - Headache: brief, self‑limiting discomfort. - Injection site pain: soreness or mild irritation at the venipuncture site. - Transient hypotension: short‑duration drop in blood pressure without clinical sequelae.

Serious or Rare Side Effects: - Allergic reaction: urticaria, bronchospasm, or anaphylaxis requiring emergency care. - Severe hypotension: prolonged blood pressure fall with dizziness or syncope. - Seizure: rare occurrence possibly related to cerebral hypoxia.

When using Ioflupan, clinicians should observe the following precautions to ensure patient safety and product integrity. - Pregnancy: safety not established; avoid use unless benefit outweighs potential risk. - Breastfeeding: unknown excretion; consider discontinuation of nursing during and after administration. - Renal impairment: reduced clearance may increase radiation exposure; adjust imaging schedule if necessary. - Concomitant dopamine‑affecting drugs: agents such as dopamine agonists or antagonists can alter tracer binding and affect image interpretation. - Pediatric use: not validated in children; reserve for adult patients only. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Ioflupan can interact with other substances that influence dopamine transporter activity or imaging results.

Major Interactions (Avoid): - Dopamine agonists (e.g., ropinirole, pramipexole): may compete for DAT binding and reduce tracer uptake. - Antipsychotics (e.g., haloperidol, risperidone): block DAT and can lead to false‑negative imaging. - Other radiopharmaceuticals administered within 24 h: may cause signal overlap and compromise image quality.

Moderate Interactions (Monitor Closely): - Thyroid blocking agents (e.g., potassium iodide): may affect systemic distribution of the radiotracer. - Renal function modifiers (e.g., diuretics): can alter clearance and radiation dose. - Caffeine or nicotine: may modestly influence dopamine turnover and should be noted.